Medtronic Stock Jumps As Earnings Beat Fuels Bullish Re-Rating

Medtronic plc. stocks have been trading up by 6.07 percent after upbeat earnings and guidance strengthened investor confidence.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading MDT

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways Traders Need To Know

Q4 numbers from Medtronic came in strong, with $1.55 EPS matching estimates and $9.81B revenue topping the $9.61B consensus on the best annual growth in a decade.
Shares of MDT spiked about 5–6% after the Q4 beat and growth outlook, though the stock is still down roughly 19% year-to-date, keeping it in “recovery story” territory for active traders.
Fiscal 2027 guidance calls for EPS of $5.90–$6.00, slightly under the $6.06 Street view, but assumes 6.75%–7.25% organic revenue growth backed by a loaded product pipeline.
BTIG upgraded MDT to Buy with a $90 target, while Mizuho and Needham trimmed targets but stayed bullish, arguing the stock looks undervalued versus its growth setup.
The company lifted its quarterly dividend to $0.72 and is plowing cash into growth platforms like the Hugo robotic surgery system and ICE catheter technologies for its cardiac ablation business.

Live Update At 10:02:48 EDT: On Thursday, June 04, 2026 Medtronic plc. stock [NYSE: MDT] is trending up by 6.07%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MDT just reminded the market it is still one of the heavyweights in medical devices. Fiscal Q4 revenue landed at $9.81B, nicely ahead of the $9.61B consensus, while adjusted EPS of $1.55 matched expectations. More important for traders, Medtronic posted its strongest annual top-line growth in a decade, with nearly 10% total revenue growth and 6.6% organic growth. That kind of acceleration matters in a slow-growth healthcare tape.

On the chart, the reaction was sharp. MDT closed at $77.95 on 2026/06/03 and ripped to $82.65 on 2026/06/04, a gap-and-go move of about 6%. Intraday, the stock opened near $80, surged through $81, and pressed toward $82.79, holding gains into the close. That tells traders real buyers were stepping in, not just algos fading news.

More Breaking News

Under the hood, MDT’s fundamentals back the move. Gross margin sits near 64.9%, EBITDA margin around 26.4%, and pretax margin close to 16.9%. A P/E of 20.6 and price-to-sales of 2.67 are not stretched for a global leader with a $33.54B revenue base and accelerating growth. Debt metrics look manageable, with total debt-to-equity at 0.57 and a current ratio of 2.5. For active traders, this is a classic “fundamentally solid name finally waking up on the chart” setup.

Why Traders Are Watching MDT After This Breakout

The core of the MDT story right now is simple: earnings momentum plus a valuation re-think. Medtronic beat fiscal Q4 expectations and guided to continued earnings and organic revenue growth, and the stock answered with a 5–6% surge on heavy demand. That move came while the broader healthcare sector was only modestly positive, showing Medtronic was trading on its own catalyst, not just riding beta.

BTIG’s upgrade from Neutral to Buy with a $90 price target added fuel. The firm called out consistent mid-single-digit organic growth, an improving trajectory, and undervaluation versus peers. They also flagged MDT’s fiscal 2027 EPS guide as conservative, with room to raise later. For traders, that reads as “beat-and-raise potential,” a pattern that often supports multi-quarter trends when execution holds.

Even the price-target cuts line up bullish. Mizuho trimmed its target from $120 to $100 but kept an Outperform rating, saying the recent selloff went too far and that MDT trades below its usual forward P/E despite a better growth outlook into 2027. Needham followed a similar script, cutting its target to $101 from $120 while reiterating Buy after Medtronic beat Q4 and guided revenue above consensus. Their call: MDT is early in a new product cycle set to drive faster organic growth.

On the growth side, Medtronic guided fiscal 2027 EPS to $5.90–$6.00, just under the $6.06 consensus. Bears will focus on that shortfall. But bulls point to the 6.75%–7.25% organic revenue growth outlook and a pipeline that management is funding aggressively. MDT is advancing its Hugo robotic-assisted surgery platform in the U.S., expanding indications and adding new instruments, and it’s investing in intracardiac echocardiography catheter names like Beluga Medical and CardioACC to strengthen its cardiac ablation franchise. Those are exactly the types of high-tech platforms that can push procedure volumes and pricing power for years.

Layer on a higher quarterly dividend of $0.72 per share ($2.88 annualized), and MDT is signaling confidence in its cash flow while still funding R&D and tuck-in M&A. That blend of yield, growth, and a re-rating narrative is why short-term and swing traders are now glued to the MDT tape.

Conclusion

For traders, MDT has shifted from sleepy large-cap to active watchlist name. The stock is up sharply on the Q4 beat and bullish guidance, yet still down about 19% year-to-date. That disconnect is what makes Medtronic interesting here: the fundamentals and analyst commentary say “turnaround and acceleration,” while the longer-term chart still reflects years of frustration.

Medtronic’s guidance for high-single-digit organic growth into fiscal 2027, backed by platforms like Hugo robotics and the expanding cardiac ablation ecosystem, gives the growth crowd something real to track. At the same time, MDT’s dividend hike to $0.72 per quarter underscores balance sheet strength and steady cash generation. Analysts from BTIG, Mizuho, and Needham, despite trimming some targets, are leaning bullish and framing MDT as undervalued with upside as the new product cycle unfolds.

For active traders, the playbook is not about hoping. It is about planning. MDT’s recent gap over $80 now becomes a key area to watch for support, while any push toward analyst targets will test the strength of this new trend. As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.” MDT’s current move gives traders all three elements to monitor closely. As Tim Sykes likes to say, “Patterns repeat, but only for traders who are prepared and disciplined enough to recognize them.” This is education, not advice — but Medtronic just created a textbook case of how strong news, improving fundamentals, and a clean technical breakout can line up in a large, liquid name.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!